For example, ≥ 30% of patients that develop metastatic, castration-resistant PCa have AR-negative (AR−) tumors [3] and 15–30% of BCa patients that develop endocrine resistance have tumors with reduced or lost ERα accumulation [1, 4]. The gene discussed is AR; the disease is posterior cortical atrophy.